A detailed history of Huntington National Bank transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Huntington National Bank holds 230 shares of BPMC stock, worth $20,398. This represents 0.0% of its overall portfolio holdings.

Number of Shares
230
Previous 177 29.94%
Holding current value
$20,398
Previous $19,000 10.53%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$84.1 - $120.5 $4,457 - $6,386
53 Added 29.94%
230 $21,000
Q2 2024

Aug 08, 2024

SELL
$85.18 - $108.78 $9,625 - $12,292
-113 Reduced 38.97%
177 $19,000
Q1 2024

May 03, 2024

BUY
$73.17 - $99.79 $439 - $598
6 Added 2.11%
290 $27,000
Q4 2023

Feb 07, 2024

SELL
$43.96 - $92.84 $3,824 - $8,077
-87 Reduced 23.45%
284 $26,000
Q3 2023

Nov 08, 2023

BUY
$46.9 - $66.0 $5,018 - $7,062
107 Added 40.53%
371 $18,000
Q2 2023

Aug 11, 2023

SELL
$42.2 - $66.37 $464 - $730
-11 Reduced 4.0%
264 $16,000
Q1 2023

May 10, 2023

SELL
$37.97 - $50.0 $379 - $500
-10 Reduced 3.51%
275 $12,000
Q4 2022

Feb 09, 2023

BUY
$41.06 - $66.48 $4,557 - $7,379
111 Added 63.79%
285 $12,000
Q1 2022

May 10, 2022

BUY
$54.1 - $110.08 $649 - $1,320
12 Added 7.41%
174 $11,000
Q4 2021

Jan 21, 2022

SELL
$94.25 - $115.99 $8,388 - $10,323
-89 Reduced 35.46%
162 $17,000
Q3 2021

Oct 28, 2021

SELL
$80.98 - $109.47 $6,316 - $8,538
-78 Reduced 23.71%
251 $26,000
Q2 2021

Jul 30, 2021

BUY
$82.78 - $101.0 $9,271 - $11,312
112 Added 51.61%
329 $29,000
Q1 2021

Apr 12, 2021

BUY
$90.71 - $108.28 $2,086 - $2,490
23 Added 11.86%
217 $21,000
Q4 2020

Jan 11, 2021

SELL
$92.08 - $124.48 $6,906 - $9,336
-75 Reduced 27.88%
194 $22,000
Q3 2020

Oct 30, 2020

BUY
$66.45 - $92.7 $1,129 - $1,575
17 Added 6.75%
269 $25,000
Q2 2020

Jul 30, 2020

BUY
$57.09 - $79.27 $14,386 - $19,976
252 New
252 $20,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.3B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Huntington National Bank Portfolio

Follow Huntington National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Huntington National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Huntington National Bank with notifications on news.